Navigation Links
Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
Date:7/17/2008

y $1.4 billion, an increase of 16 percent. Double-digit growth across the portfolio was the result of robust sales of plasma-based therapies, products used for the treatment of hemophilia and immune disorders, biosurgery products and strong demand for the company's encephalitis vaccine.

Medication Delivery sales grew 12 percent in the quarter to approximately $1.2 billion, driven by strong international sales of IV therapy products and injectable drugs, as well as anesthesia products globally. Renal sales increased 8 percent to approximately $600 million as a result of an increase in peritoneal dialysis patients in many markets around the world.

The company continues to advance its product pipeline across its business portfolio. Investments in research and development in the quarter totaled $222 million, reflecting an increase of 25 percent over the prior-year period.

Six-Month Results

For the first six months of 2008, Baxter's net income totaled $973 million and increased 17 percent, with earnings per diluted share increasing 21 percent to $1.52. On an adjusted basis, Baxter's net income of $1.0 billion increased 16 percent from $880 million last year. Adjusted earnings per diluted share for the six-month period of $1.59 increased 20 percent, from $1.33 per diluted share in the prior year period.

Baxter's worldwide sales grew 10 percent in the first half of the year to $6.1 billion, an increase from $5.5 billion last year. Excluding the impact of foreign exchange, sales growth for the first six months of the year was 3 percent. Sales within the United States totaled $2.4 billion, an increase of 4 percent over the same period last year, and international sales grew 15 percent (or 3 percent excluding the impact of foreign exchange) to $3.6 billion.

Third Quarter and Full-Year 2008 Outlook

As a result of the strong performance in the first half of the year, Baxter is raising its financial outlook for full-year 2008. The
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related biology technology :

1. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
2. Baxters Board of Directors Declares Quarterly Dividend
3. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
4. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals
5. Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
6. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
7. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
8. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
9. Baxter Declares Quarterly Dividend
10. Baxter Provides Update on Heparin Reactions
11. Baxters Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Pittcon is ... will present a session on chemical spectroscopic imaging at JASIS 2015 (Japan Analytical ... Asia’s largest analytical and scientific instruments show which will be held at International ...
(Date:8/28/2015)... ... 28, 2015 , ... Since the initial launch of FireflySci Inc. (FFS) in early 2015, the ... service. Images such as the Fonz in a lab coat and Large Marge have ... humdrum spectroscopy field. , FireflySci is proud to be the only cuvette manufacturer ...
(Date:8/27/2015)... -- Neogen Corporation (NASDAQ: NEOG ) announced today that ... Kingdom -based Lab M Holdings, a developer, manufacturer ... Lab M was founded in 1971, ... testing and diagnostic products for the global food, water, ... into more than 70 countries worldwide, and has several ...
(Date:8/27/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a ... medicine, today announced that executives from the company will ... September.  , Pedro Lichtinger , ... 17th Annual Global Investment Conference on Wednesday, September 10, ... Hotel in New York City . ...
Breaking Biology Technology:U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Neogen acquires U.K.-based Lab M Holdings 2Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2
... ... new partner and sponsor in Life Line Screening. The two companies aim to ... abdominal aortic aneurysm and , peripheral arterial disease screening . Life Line ... its customers can easily donate money to the foundation. , ...
... , SAN DIEGO, Dec. 9 ... top-line efficacy and safety results from the Tulip PETAL Study ... proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in ... data from the Tulip PETAL Study are consistent with what ...
... , Nashville, Tenn., Dec. 9 Cumberland Pharmaceuticals ... entered into an exclusive agreement with DB Pharm Korea Co. ... ( ibuprofen ) Injection in South Korea. Designed to treat pain ... U.S. Food and Drug Administration and launched by Cumberland in the ...
Cached Biology Technology:Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4
(Date:8/20/2015)... Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... joined The Smart Card Alliance and the EMV Migration ... and the Smart Card Alliance Latin America (SCALA) Chapter ... peers and thought leaders promoting adoption of smart card ...
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
(Date:8/10/2015)... TELTOW, Germany , August 10, 2015 ... a world leader in Eye Tracking Technology for more ... OEM Eye Tracking Platform for integration into all consumer ... reference designs for seamless integration of eye tracking into ... HMDs and augmented reality smart glasses. Omnivision,s leading sensor ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... Studies show the incidence of diabetes in dogs has increased ... Missouri veterinarians have changed the way veterinarians treat diabetes in ... humans. Dogs are susceptible to type 1, insulin-dependent diabetes. ... because their bodies do not produce enough insulin, a hormone ...
... around the world have forced many species to the brink ... multiple causes that are still not fully understood, researchers conclude ... causative factor is often missing the larger picture, they said, ... don,t consider the totality of causes or could even ...
... April 25, 2011 - Call them the Jason Bournes of ... secret agents, some bacteria avoid antibiotic treatments by essentially shutting ... says Thomas Wood, professor in the Artie McFerrin Department of ... elaborate survival mechanism is explained in the online April edition ...
Cached Biology News:MU researchers pioneer animal diabetes treatment 2Catastrophic amphibian declines have multiple causes, no simple solution 2Catastrophic amphibian declines have multiple causes, no simple solution 3'Going off the grid' helps some bacteria hide from antibiotics 2'Going off the grid' helps some bacteria hide from antibiotics 3